or inhibitors of CYP3A4 that also have the potential to prolong the QT interval such as dolasetron.
Telaprevir: Close clinical monitoring is advised when administering dolasetron with telaprevir due to an increased potential for dolasetron-related adverse events. If dolasetron dose adjustments are made, re-adjust the dose upon completion of telaprevir treatment. Although this interaction has not been studied, predictions about the interaction can be made based on the metabolic pathway of dolasetron. Dolasetron is partially metabolized by the hepatic isoenzyme CYP3A4; telaprevir inhibits this isoenzyme. Coadministration may result in elevated dolasetron plasma concentrations.
Telavancin: Due to a possible risk for QT prolongation and torsade de pointes (TdP), dolasetron and telavancin should be used together cautiously.Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Telavancin has been associated with QT prolongation.
Telithromycin: Due to a possible risk for QT prolongation and torsade de pointes (TdP), dolasetron and telithromycin should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Telithromycin is associated with QT prolongation and torsades de pointes (TdP) and is a strong inhibitor of the CYP3A4 isoenzyme. Coadministration with other drugs that prolong the QT interval and are CYP3A4 substrates, such as dolasetron, may result in increased concentrations of dolasetron and an increased risk of adverse reactions, such as QT prolongation.
Telotristat Ethyl: Use caution if coadministration of telotristat ethyl and dolasetron is necessary, as the systemic exposure of dolasetron may be decreased resulting in reduced efficacy. If these drugs are used together, monitor patients for suboptimal efficacy of dolasetron; consider increasing the dose of dolasetron if necessary. Dolasetron is a CYP3A4 substrate. The mean Cmax and AUC of another sensitive CYP3A4 substrate was decreased by 25% and 48%, respectively, when coadministered with telotristat ethyl; the mechanism of this interaction appears to be that telotristat ethyl increases the glucuronidation of the CYP3A4 substrate.
Tetrabenazine: Due to a possible risk for QT prolongation and torsade de pointes (TdP), dolasetron and tetrabenazine should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the r |
